Clostridium difficile infection (CDI) has emerged as a significant nosocomial infection over the years with increased incidence, recurrence and need for hospitalization. About 15% to 30% of patients who initially respond to antimicrobial therapy experience recurrent CDI (rCDI). After the first recurrence, the risk of subsequent recurrence significantly increases to about 45–65% of patients.
As per DelveInsight’s estimates, there were approximately 669K incident cases of CDI in the 7MM, in 2021, with the United States accounting for nearly 70% of all the cases.
Current Clostridium difficile Infection Treatment Landscape
The current treatment regi...
